Russian Federation
Russian Federation
Russian Federation
Thromboembolic complications in individuals with high cardiometabolic risk are among the leading causes of cardiovascular mortality in the world. Rivaroxaban is an oral inhibitor of factor X (Stuart-Prower factor) approved for prevention of thromboembolic complications in many countries. The article evaluates clinical efficiency of rivaroxaban in reducing the possibility of development of thromboembolic complications in patients with high cardiometabolic risk with non-valvular atrial fibrillation coupled with obesity, arterial hypertension and hyperlipidemia.
rivaroxaban, visceral obesity, arterial hypertension, atrial fibrillation, cardiometabolic risk
1. Benjamin E.J., Muntner P., Alonso A. et al. Heart disease and stroke statistics – 2019 update: a report from the American Heart Association // Circulation. – 2019; 139(10):e56–e528. Doi:https://doi.org/10.1161/CIR.0000000000000659
2. O'Keefe E.L., Sturgess J.E., O'Keefe J.H. et al. Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification // Am. J. Cardiol. – 2021; 160:46-52. Doi:https://doi.org/10.1016/j.amjcard.2021.08.042
3. Goluhova E.Z., Gromova O.I., Bulaeva N.I. i dr. Epikardial'nyy zhir i fibrillyaciya predserdiy: rol' profibrogennyh mediatorov // Kardiologiya. – 2018; 58(7):59–65. Doi:https://doi.org/10.18087/cardio.2018.7.10145
4. Ott A.V., Chumakova G.A., Veselovskaya N.G. Epikardial'noe ozhirenie kak odin iz osnovnyh kriteriev metabolicheski tuchnogo fenotipa ozhireniya // Sibirskoe medicinskoe obozrenie. – 2017;(4): 44-53. Doi:https://doi.org/10.20333/2500136-2017-4-44-53
5. Svistunov A.A., Osadchuk M.A., Vasil'eva I.N., Mironova E.D. Sindrom sosudistogo stareniya pri metabolicheskih narusheniyah i arterial'noy gipertenzii. Vozmozhnosti vazoprotektivnogo vliyaniya kombinirovannoy antigipertenzivnoy terapii // Medicinskiy vestnik MVD. – 2024; 4 (131):49-56. Doi:https://doi.org/10.52341/20738080_2024_131_4_49
6. Chulkov V.S., Minina E.E., Chulkov Vl.S., Tkachenko P.E. Ozhirenie i risk razvitiya venoznyh tromboembolicheskih oslozhneniy // Profilakticheskaya medicina. – 2022; 25(10):54–60. Doi:https://doi.org/10.17116/profmed20222510154
7. Arutyunov G.P., Babak S.L., Vasyuk Yu.A. i dr. Diagnostika, lechenie, profilaktika ozhireniya i associirovannyh s nim zabolevaniy. Nacional'nye klinicheskie rekomendacii, 2017. Dostup po ssylke: https: //scardio.ru/ content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf
8. Hromylev A.V. Patogeneticheskie aspekty aterotromboticheskogo riska pri ozhirenii i trombofilii // Akusherstvo, ginekologiya i reproduktologiya. – 2015; 9(3):45–52. Doi:https://doi.org/10.17749/2070- 4968.2015.9.3.045-052
9. Osadchuk M.A., Vasil'eva I.N., Kozlov V.V., Mitrohina O.I. Metabolicheskiy sindrom kak faktor riska onkogeneza // Profilakticheskaya medicina. – 2023; 26(1):70–79. Doi:https://doi.org/10.17116/profmed20232601170
10. Lu B., Huang L., Cao J. et al. Adipose tissue macrophages in aging-associated adipose tissue function // J. Physiol. Sci. – 2021; 71(1), 38. Doi:https://doi.org/10.1186/s12576-021-00820-2
11. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome // Mol. Cell. Endocrinol. – 2010; 314:1–16. Doi:https://doi.org/10.1016/j.mce.2009.07.031
12. Xiang P., Blanchard V., Francis G.A. Smooth Muscle Cell-Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location // Front. Physiol. – 2022; 13:921597. Doi:https://doi.org/10.3389/fphys.2022.921597
13. Shu, H., Cheng, J., Li, N. et al. Obesity and atrial fibrillation: a narrative review from arrhythmogenic mechanisms to clinical significance // Cardiovasc. Diabetol. – 2023; 22, 192. Doi:https://doi.org/10.1186/s12933-023- 01913-5
14. Drapkina O.M., Nikolaeva M.V. Patogeneticheskie mehanizmy razvitiya fibrillyacii predserdiy pri ozhirenii // Racional'naya farmakoterapiya v kardiologii. – 2016; 12(5):582-589. Doi:https://doi.org/10.20996/1 81 9-6446-2016-12-5-582-589
15. Klinicheskie rekomendacii Rossiyskogo kardiologicheskogo obschestva «Fibrillyaciya i trepetanie predserdiy. – 2025. Dostup po ssylke: https: //scardio.ru/rekomendacii/rekomendacii_rko/fibrillyaciya_i_trepetanie_predserdiy_2025
